Navigation Links
Immucor Announces Record Fiscal Third Quarter Results
Date:4/1/2008

http://www.immucor.com" target="_new">http://www.immucor.com.

Statements contained in this press release that are not statements of historical fact are "forward-looking statements" as that term is defined under federal securities laws, including, without limitation, all statements concerning Immucor's expectations, beliefs, intentions or strategies for the future. Forward-looking statements may be identified by words such as "plans," "expects," "believes," "anticipates," "estimates," "projects," "will," "should" and other words of similar meaning used in conjunction with, among other things, discussions of future operations, financial performance, product development and new product launches, FDA and other regulatory applications and approvals, market position and expenditures. Factors that could cause actual results to differ materially from those expressed in any forward-looking statement include the following: lower than expected market acceptance of the Company's new Galileo Echo instrument; the decision of customers to defer capital spending; the inability of customers to efficiently integrate our instruments into their blood banking operations; increased competition in the sale of instruments and reagents, particularly in North America; product development or regulatory obstacles; the ability to hire and retain key managers; changes in interest rates; fluctuations in foreign currency conversion rates; the ability of the Company's Japanese subsidiary to attain expected revenue, gross margin and net income levels; the outcome of any legal claims or regulatory investigations known or unknown; delays in regulatory approvals required to manufacture products previously produced in Houston; higher than expected manufacturing consolidation costs; the unexpected application of different accounting rules; and general economic conditions. Further risks are detailed in the Company's filings with the Securities and Exchange Commission. Investors are cautioned no
'/>"/>

SOURCE Immucor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Immucor Schedules First Quarter Earnings Release and Conference Call
2. Immucor Announces Record Fiscal First Quarter Revenues
3. Immucor, Inc. Appoints New Chief Financial Officer
4. Immucor Announces Update to Second Quarter Conference Call Number
5. Immucor, Inc. Adds Director to Board
6. Immucor Schedules Third Quarter Earnings Release and Conference Call
7. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
8. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
9. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
10. HEI, Inc. Announces Sale of RFID Division Assets
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... ... August 29, 2015 , ... "I have been a licensed ... "I specialize in manual therapy, and my invention will provide headache sufferers a ... additional muscle dysfunction throughout the body." , They developed THE RELIEVER to alleviates ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder and President ... to increase acceptance of the chiropractic field in the military. All too often VA ... Although Chiropractic was made available to the VA program over a decade ago, the ...
(Date:8/29/2015)... CA (PRWEB) , ... August 29, 2015 , ... ProDrop ... X . Each preset contains 15 seconds of unique footage that users can shrink ... rise, fall, zoom, attract and more. Users can customize color, brightness, scale, speed, range, ...
(Date:8/29/2015)... ... ... The popular television program VOICES IN AMERICA, hosted by legendary star of ... an entire short segment to the subject of diabetes. Diabetes is a debilitating health ... basis, but recent advancements in medical science may prove to be a significant breakthrough ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... management, Decatur County Memorial Hospital recently transitioned management companies to partner with Wound ... Management for their outpatient wound center. , Transitioning wound care management providers ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... East Primary Care Trust will be banned from smoking, even ... their identification// badge or uniform. The ban on smoking which ... and other people who visit the premises of the Trust. ... been called upon to give its approval for the new ...
... has called upon the NHS to make improvements in the ... that children who are terminally ill should not be compelled ... been issued by the Department of Health which insists ... which is inclusive of caring at home like nurse led ...
... the UT Southwestern Medical Center have found that brain ... them training using robotic treadmill. This is believed to ... paralysis following spinal cord injury. ,In the ... injured persons are capable of activating areas of brain ...
... that Alzheimer's disease represents a neuro-endocrine disorder that ... progresses // with severity of neuro-degeneration. ... the Journal of Alzheimer's Disease, researchers demonstrate that ... brain during the early stages of Alzheimer's disease, ...
... has to pay more attention to early detection and prevention ... terms of human lives//, according to experts participating in the ... the country. ,'Around 800,000 new cancer cases are being ... be on early detection and preventive care,' Surabhi Kakar, Secretary ...
... causes for the common depression have been identified by ... treatment for the ailment.// The major depressive disorder is ... quite a number of effective treatments for depression, even ... are not well known. ,William S. Gilmer, MD, ...
Cached Medicine News:Health News:Paralyzed Patients Can Be Trained To Walk With Robotic Treadmill 2Health News:Alzheimer's a new type of diabetes: Study 2Health News:India Needs To Pay More Attention To Detecting Cancer 2Health News:Causes Of Common Depression Identified 2
(Date:8/28/2015)... Aug. 28, 2015 , Joint ... Ra from Biostar , Published in ,Stem Cells ... of lifespan through multiple IV administration of Adipose-derived MSC ... life expectancy found , Commercialization within 5 years ... the possibility that adult mesenchymal stem cells (MSCs) may ...
(Date:8/28/2015)... Massachusetts y LONDRES, 28 de agosto ... AEX: PHIA) anunció hoy su participación en el  ... exhibirá sus soluciones cardiológicas más recientes y novedosas, ... Cardiovascular, que conectan a las personas y la ... de ayudar a diagnosticar, guiar los tratamientos y ...
(Date:8/28/2015)... -- The global mHealth market ... 2020, growing at a CAGR of 47.6% from 2013 ... View Research, Inc. Monitoring services is expected to grow ... 2020.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... of chronic diseases such as cancer, heart ailments, and ...
Breaking Medicine Technology:Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5
... SAN FRANCISCO , June 1 Prostate ... on FIRMAGON® (degarelix for injection) after one year of ... results of a Phase III extension study(1) presented here ... commonly used in monitoring prostate cancer patients, treatment response, ...
... , MORRISTOWN, N.J. , June 1 Watson ... Laboratories, Inc. has filed with the Securities and Exchange Commission a ... announced agreement under which Watson would acquire the U.S. rights to ... of Columbia common stock.   , ...
Cached Medicine Technology:Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 2Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 3Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 4Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 5Watson Confirms Columbia Laboratories' Filing of Definitive Proxy Relating to Watson's Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line 2Watson Confirms Columbia Laboratories' Filing of Definitive Proxy Relating to Watson's Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line 3Watson Confirms Columbia Laboratories' Filing of Definitive Proxy Relating to Watson's Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line 4Watson Confirms Columbia Laboratories' Filing of Definitive Proxy Relating to Watson's Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line 5